title: Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring?
abstract: Advanced bronchial carcinomas by means of perfusion and peak enhancement using dynamic contrast-enhanced multislice CT are characterized. Twenty-four patients with advanced bronchial carcinoma were examined. During breathhold, after injection of a contrast-medium (CM), 25 scans were performed (1 scan/s) at a fixed table position. Density-time curves were evaluated from regions of interest of the whole tumor and high- and low-enhancing tumor areas. Perfusion and peak enhancement were calculated using the maximum-slope method of Miles and compared with size, localization (central or peripheral) and histology. Perfusion of large tumors (> 50 cm3) averaged over both the whole tumor (P = 0.001) and the highest enhancing area (P = 0.003) was significantly lower than that of smaller ones. Independent of size, central carcinomas had a significantly (P = 0.04) lower perfusion (mean 27.9 ml/min/100 g) than peripheral ones (mean 66.5 ml/min/100 g). In contrast, peak enhancement of central and peripheral carcinomas was not significantly different. Between non-small-cell lung cancers and small-cell lung cancers, no significant differences were observed in both parameters. In seven tumors, density increase after CM administration started earlier than in the aorta, indicating considerable blood supply from pulmonary vessels. Tumor perfusion was dependent on tumor size and localization, but not on histology. Furthermore, perfusion CT disclosed blood supply from both pulmonary and/or bronchial vessels in some tumors.
authors.affiliation: Department of Oncological Diagnostics and Therapy, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Kiessling
authors.forename: J
authors.initials: J
authors.lastname: Boese
authors.forename: C
authors.initials: C
authors.lastname: Corvinus
authors.forename: J R
authors.initials: JR
authors.lastname: Ederle
authors.forename: I
authors.initials: I
authors.lastname: Zuna
authors.forename: S O
authors.initials: SO
authors.lastname: Schoenberg
authors.forename: G
authors.initials: G
authors.lastname: Brix
authors.forename: A
authors.initials: A
authors.lastname: Schmähl
authors.forename: S
authors.initials: S
authors.lastname: Tuengerthal
authors.forename: F
authors.initials: F
authors.lastname: Herth
authors.forename: H U
authors.initials: HU
authors.lastname: Kauczor
authors.forename: M
authors.initials: M
authors.lastname: Essig
mesh_terms: D000328:Adult; D000368:Aged; D002283:Carcinoma, Bronchogenic / Q000000981:diagnostic imaging* / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000000981:diagnostic imaging* / Q000628:therapy; D003287:Contrast Media; D005260:Female; D006801:Humans; D007479:Iopamidol / Q000031:analogs & derivatives*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed
chemical_list: D003287:Contrast Media; C057937:iomeprol; D007479:Iopamidol